....
it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done... despite neutral imaging results, adalimumab did improve other key markers of inflammation in the blood including glyca, crp, tnf, and il-6.. understanding cholesterol effects of adalimumab by new techniques was another goal of gelfand and mehta's study...